Semaglutide absorption: what actually happens inside the body

The myth: 'the tablet just works like any other pill'

It is tempting to assume that swallowing a medicine is simpler than injecting one. With Wegovy tablets, the reality is the opposite. Oral semaglutide faces an immediate problem: the digestive system treats proteins and peptide-like molecules as food, breaking them down long before they reach the bloodstream. Novo Nordisk solved this with a co-formulation approach. Each tablet pairs semaglutide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, known as SNAC, which temporarily raises the pH directly around the tablet's surface and opens a transient absorption window through the stomach lining itself, not the small intestine, where most drugs are absorbed.

This mechanism is genuinely novel. The MHRA approved Wegovy tablets on 11 June 2026 as the first oral GLP-1 medicine licensed in the UK for weight management. But the approval came with firm conditions baked into the design: the tablet must be taken first thing in the morning, on a completely empty stomach, with no more than a small amount of plain water. Thirty minutes must pass before any food, drink (including coffee or tea), or other oral medicines. The stomach lining's receptiveness to SNAC drops sharply the moment bile, fat or other fluids enter the system. A patient who takes the tablet with their usual morning cup of tea, or who eats breakfast after only fifteen minutes, may absorb a fraction of the intended dose without realising anything has gone wrong. That is the practical problem hidden inside 'it's just a tablet'.

The NHS medicines page for semaglutide covers the general pharmacology; the patient information leaflet, available via the eMC, gives the exact fasting instructions for the tablet form.

How the injection route sidesteps the problem entirely

The subcutaneous injection bypasses the gut completely. Semaglutide deposited under the skin is picked up slowly by the lymphatic system and capillaries in the surrounding tissue, reaching peak plasma concentration over roughly one to three days. Its half-life is approximately one week, which is what makes a once-weekly schedule viable, concentrations stay high enough between doses to keep appetite suppression consistent.

Absorption rate from the injection does vary slightly by site. The abdomen, thigh and upper arm are all licensed sites; rotation matters for tissue health rather than for major pharmacokinetic differences, though the abdomen tends to give the most consistent absorption in clinical practice. Temperature matters too: a pen that has been left unrefrigerated for longer than the SmPC permits may have degraded before the dose is delivered. The patient information leaflet holds the exact storage window, and that is the right place to check it.

For most people reading this page, the relevant question is whether the injectable or tablet form suits their life better. If you travel often and cannot guarantee a fridge, or if injections feel like a barrier, the tablet may seem appealing. If your mornings are unpredictable (a toddler who derails breakfast timing, or a commute that makes fasting difficult) that changes the calculation. Our clinical team, led by our independent prescribers, works through exactly these practical factors during consultation. There is no single right answer; it depends on routine, preference and medical history together.

What reduces absorption in practice, and what the trial data actually measured

The OASIS 4 phase-3 trial, which supported the MHRA approval of Wegovy tablets, reported average weight loss of around 13.6% over 64 weeks against placebo. Among participants who stayed fully adherent to the fasting protocol, that figure rose to approximately 16.6%. The gap between those two numbers is a direct readout of what imperfect absorption does in real-world conditions. It is not a small difference.

For the injection form, the published evidence from the STEP 1 trial (available in full in the New England Journal of Medicine) showed around 15% average weight reduction over 68 weeks at the 2.4mg maintenance dose. A higher dose of 7.2mg, approved by the MHRA in early 2026, has reported around 20.7% average loss over 72 weeks in trial data, though availability of specific pen formats is confirmed at consultation rather than assumed.

Other factors that can interfere with effective absorption of the injection: injecting into scar tissue or the same site repeatedly (slows uptake), injecting into a pen that was frozen at any point (degrades the medicine), or missing doses and restarting at the wrong point in the titration schedule. None of these are reasons to panic if they have happened once; they are reasons to discuss next steps with a prescriber rather than self-adjusting. If you are thinking about the cost context for treatment alongside these practical considerations, our treatment page sets out what is included in a single transparent price.

One timing note worth making plainly: absorption problems caused by incorrect administration can build up quietly over several weeks. Someone who started treatment in January, followed the instructions carefully, and then gradually let the fasting window slip to twenty minutes by March may not notice the change in effect straight away. The most common point where this drift happens is a change in routine, a new job, a holiday, or simply the habit becoming so automatic that the details get fuzzy. Pausing to re-read the patient information leaflet once every few months is not overcautious; it is just good practice.

How a prescriber decides which form is appropriate

Semaglutide for weight management is licensed in the UK under the brand Wegovy, in both injectable and tablet forms. The range of semaglutide options available reflects meaningfully different absorption mechanisms, not just different routes of administration. A prescriber looking at your case will consider whether you have any conditions affecting gastric motility or stomach acid production (which can influence oral absorption), what other medicines you take in the morning and whether a 30-minute gap is manageable with them, and whether you have any previous history of GI side effects that might make the injection or the tablet a better fit.

The titration schedule also matters. Both forms start at a low dose to allow the body to adjust, nausea and digestive discomfort are most common in the first few weeks and after each dose increase, as the gut adapts to the medicine's effects on gastric emptying. That settling-in process is not a sign of poor absorption; it is the expected pharmacological response. The dose ladder for Wegovy tablets runs from 1.5mg through 4mg and 9mg to the 25mg maintenance level, with at least a month at each step.

If you are weighing up whether semaglutide or another licensed treatment is the right fit for your circumstances, the weight-loss treatment overview gives a grounded comparison without the sales pressure. A consultation with our prescribers is the right starting point for a decision that depends this much on individual detail. Speak to our prescribers, there is no charge for the consultation, and no obligation to proceed.